Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery

Area of Science:

• Cardiovascular Surgery
• Biomaterials Science
• Anesthesiology

Background:

• Coronary artery bypass grafting (CABG) frequently requires cardiopulmonary bypass (CPB).
• Minimizing blood loss and transfusion needs during CPB is a critical clinical objective.
• Heparin-coated circuits are designed to reduce the inflammatory response and coagulopathy associated with CPB.

Purpose of the Study:

• To evaluate the efficacy of heparin-coated extracorporeal circuits in reducing bleeding, transfusion requirements, and preserving platelet counts.
• To compare outcomes between heparin-coated and standard uncoated circuits in patients undergoing primary CABG with full heparinization.

Main Methods:

• A randomized, double-blind study was conducted at a tertiary-care academic medical center.
• Eighty-eight patients undergoing primary CABG requiring CPB were randomized to receive either a heparin-coated or an uncoated CPB circuit.
• Activated coagulation time was maintained >480 seconds with heparin; platelet counts and 24-hour mediastinal drainage were measured.

Main Results:

• No significant difference in 24-hour mediastinal chest tube drainage was observed between the heparin-coated (1015 mL) and uncoated (1040 mL) groups (p = 0.91).
• Mean platelet counts during CPB were similar between both groups.
• The heparin-coated circuit group received significantly fewer units of allogeneic packed red blood cells (0.9 U vs 1.5 U; p = 0.04).

Conclusions:

• Heparin-coated CPB circuits, under full heparinization, did not demonstrate a significant reduction in perioperative bleeding or provide platelet sparing benefits.
• A marginal reduction in allogeneic packed red blood cell transfusion was observed with heparin-coated circuits.
• The clinical benefit of heparin-coated circuits in primary CABG appears limited to a modest decrease in red blood cell transfusion needs.